+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 140 Pages
  • July 2024
  • Region: Global
  • Grand View Research
  • ID: 5748251
Description Jump to:
The global onychomycosis market size was estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights

  • Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Treatment Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. Onychomycosis Market: Executive Summary
2.1. Market Snapshot
2.2. Type Snapshot
2.3. Treatment Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Onychomycosis Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Increasing Incidence of Onychomycosis
3.4.2. Rising Awareness About Treatment of Onychomycosis
3.4.3. Rising Awareness About Treatment of Onychomycosis
3.4.4. Growing Geriatric and Diabetic Populations
3.5. Market Restraint Analysis
3.5.1. Growing Geriatric and Diabetic Populations
3.6. Onychomycosis Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat of New Entrant
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
3.6.3. Pricing Analysis
3.6.4. Pipeline Analysis
Chapter 4. Onychomycosis Market: Type Estimates & Trend Analysis
4.1. Global Onychomycosis Market: Type Segment Dashboard
4.2. Global Onychomycosis Market: Type Movement Analysis
4.3. Global Onychomycosis Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Distal Subungual Onychomycosis
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. White Superficial Onychomycosis
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Proximal Subungual Onychomycosis
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Other Types
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Onychomycosis Market: Treatment Estimates & Trend Analysis
5.1. Global Onychomycosis Market: Treatment Segment Dashboard
5.2. Global Onychomycosis Market: Treatment Movement Analysis
5.3. Global Onychomycosis Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
5.4. Oral
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Topical
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Regional Market Dashboard
6.2. Global Regional Market Snapshot
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Competitive Scenario
6.4.1.3. Regulatory Framework/Reimbursement Framework
6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework/Reimbursement Framework
6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Competitive Scenario
6.5.1.3. Regulatory Framework/Reimbursement Framework
6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework/Reimbursement Framework
6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. Spain
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework/Reimbursement Framework
6.5.3.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework/Reimbursement Framework
6.5.4.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework/Reimbursement Framework
6.5.5.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework/Reimbursement Framework
6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework/Reimbursement Framework
6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework/Reimbursement Framework
6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Competitive Scenario
6.6.1.3. Regulatory Framework/Reimbursement Framework
6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework/Reimbursement Framework
6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework/Reimbursement Framework
6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework/Reimbursement Framework
6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework/Reimbursement Framework
6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework/Reimbursement Framework
6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Competitive Scenario
6.7.1.3. Regulatory Framework/Reimbursement Framework
6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Mexico
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework/Reimbursement Framework
6.7.2.4. Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework/Reimbursement Framework
6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Competitive Scenario
6.8.1.3. Regulatory Framework/Reimbursement Framework
6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework/Reimbursement Framework
6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework/Reimbursement Framework
6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework/Reimbursement Framework
6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company /Competition Categorization
7.2. Participant Overview
7.3. Financial Performance
7.4. Product Overview
7.5. Company Market Share Analysis
7.6. Strategy Mapping, 2023
7.6.1. Bausch Health Companies Inc.
7.6.1.1. Overview
7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.1.3. Product Benchmarking
7.6.1.4. Strategic Initiatives
7.6.2. GSK plc.
7.6.2.1. Overview
7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.2.3. Product Benchmarking
7.6.2.4. Strategic Initiatives
7.6.3. Abbott
7.6.3.1. Overview
7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.3.3. Product Benchmarking
7.6.3.4. Strategic Initiatives
7.6.4. Pfizer, Inc.
7.6.4.1. Overview
7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.4.3. Product Benchmarking
7.6.4.4. Strategic Initiatives
7.6.5. Bayer AG
7.6.5.1. Overview
7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.5.3. Product Benchmarking
7.6.5.4. Strategic Initiatives
7.6.6. Teva Pharmaceutical Industries Ltd.
7.6.6.1. Overview
7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.6.3. Product Benchmarking
7.6.6.4. Strategic Initiatives
7.6.7. Cipla Inc.
7.6.7.1. Overview
7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.7.3. Product Benchmarking
7.6.7.4. Strategic Initiatives
7.6.8. Merck & Co., Inc.
7.6.8.1. Overview
7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.8.3. Product Benchmarking
7.6.8.4. Strategic Initiatives
7.6.9. Novartis AG
7.6.9.1. Overview
7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.9.3. Product Benchmarking
7.6.9.4. Strategic Initiatives
7.6.10. Sun Pharmaceutical Industries Ltd.
7.6.10.1. Overview
7.6.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.10.3. Product Benchmarking
7.6.10.4. Strategic Initiatives
7.6.11. Moberg Pharma AB
7.6.11.1. Overview
7.6.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.6.11.3. Product Benchmarking
7.6.11.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Onychomycosis Market, By Region, 2018 - 2030 (USD Million)
Table 5 North America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 7 North America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 8 U.S. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 9 U.S. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 10 Canada Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 11 Canada Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 12 Europe Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 13 Europe Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 14 Europe Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 15 Germany Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 16 Germany Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 17 UK Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 18 UK Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 19 France Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 20 France Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 21 Italy Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 22 Italy Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 23 Spain Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 24 Spain Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 25 Denmark Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 26 Denmark Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 27 Sweden Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 28 Sweden Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 29 Norway Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 30 Norway Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 31 Asia Pacific Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Onychomycosis Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Japan Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 35 Japan Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 36 China Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 37 China Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 38 India Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 39 India Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 40 South Korea Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 41 South Korea Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 42 Australia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 43 Australia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 44 Thailand Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 45 Thailand Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 46 Latin America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 47 Latin America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 48 Latin America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 49 Brazil Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 50 Brazil Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 51 Mexico Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 52 Mexico Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 53 Argentina Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 54 Argentina Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 60 South Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 61 South Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 62 UAE Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 63 UAE Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
Table 64 Kuwait Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
Table 65 Kuwait Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Onychomycosis Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration & Growth Prospect Mapping
Fig. 15 Onychomycosis market: Type outlook and key takeaways
Fig. 16 Onychomycosis market: Type movement analysis & market share 2023 & 2030
Fig. 17 Distal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 White superficial onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Proximal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Onychomycosis market: Treatment outlook and key takeaways
Fig. 22 Onychomycosis market: Treatment movement analysis & market share 2023 & 2030
Fig. 23 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Regional Marketplace: Key Takeaways
Fig. 27 Regional Outlook, 2023 & 2030
Fig. 28 Regional Market Dashboard
Fig. 29 Regional Market: Key Takeaways
Fig. 30 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 31 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 32 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 33 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 34 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 35 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 36 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 37 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 38 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 39 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 40 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 41 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 42 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 43 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 44 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 45 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 46 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 47 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 48 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 49 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 50 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 51 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 52 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 53 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 54 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 55 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 56 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 57 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
Fig. 58 Strategy Mapping

Companies Mentioned

  • Bausch Health Companies Inc.
  • GSK plc.
  • Abbott
  • Pfizer, Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Moberg Pharma AB

Methodology

Loading
LOADING...

Related Topics

Related Reports

Onychomycosis Treatment Market by Treatment, Type - Global Forecast 2025-2030 - Product Image

Onychomycosis Treatment Market by Treatment, Type - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Onychomycosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Onychomycosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Onychomycosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Onychomycosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 126 Pages
  • Global
From
Onychomycosis Treatment Market Report by Disease Type, Treatment Type, Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Onychomycosis Treatment Market Report by Disease Type, Treatment Type, Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Dermatophytic Onychomycosis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Dermatophytic Onychomycosis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.